Compared with the individual single agents, the combination therapy (MMC + PD-L1 antibody) was found to be more effective in increasing the number of tumor-infiltrating lymphocytes (TILs) and promoting the secretion of the cytotoxic serum protease (granzyme B) from T cells to induce apoptosis of targeted cancer cells. The gene discussed is GZMB; the disease is neoplasm.